Related Experiment Video

Updated: Jul 9, 2026

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association

Maureen McMahon1, Bevra H Hahn

  • 1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA. mmcmahon@mednet.ucla.edu

Current Opinion in Immunology
|December 18, 2007
PubMed

Insights

Systemic Lupus Erythematosus (SLE) patients face higher cardiovascular risks due to inflammation and immune responses, not just traditional factors. Understanding these immune mechanisms is key to preventing atherosclerosis in SLE.

Area of Science:

  • Immunology
  • Cardiovascular Medicine
  • Rheumatology

Background:

  • Systemic Lupus Erythematosus (SLE) is increasingly associated with cardiovascular disease.
  • Patients with SLE exhibit a higher risk of atherosclerosis, independent of traditional cardiac risk factors.
  • Improved therapies have increased SLE patient longevity, highlighting the growing burden of cardiovascular events.

Purpose of the Study:

  • To investigate the inflammatory and immune mechanisms contributing to accelerated atherosclerosis in SLE.
  • To identify specific molecular mediators involved in SLE-related cardiovascular risk.
  • To elucidate the complex interplay of immune factors in lupus-driven atherosclerosis.

Main Methods:

  • Review of recent studies on SLE pathogenesis and cardiovascular complications.
  • Analysis of molecular pathways involving lipids, adhesion molecules, and cytokines.
  • Examination of the role of autoantibodies and immune complexes in atherosclerosis development.

Main Results:

  • Elevated levels of oxidized lipids (oxidized LDL, pro-inflammatory HDL) are implicated.
  • Upregulation of adhesion molecules and pro-inflammatory cytokines (MCP-1, TNF-alpha, IFN-gamma, IL-1, IL-12) observed.
  • Autoantibodies to oxidized lipids and immune complexes may contribute to atherosclerotic processes.

Conclusions:

  • Inflammatory and immune dysregulation are primary drivers of atherosclerosis in SLE.
  • A complex interplay of immune mediators underlies the increased cardiovascular risk in SLE patients.
  • Targeting these immune pathways may offer novel strategies for cardiovascular risk reduction in SLE.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...